Financial Constraints to Molecular Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst discuss the challenges of reimbursement by payers and the costs to pathology department of molecular biomarker testing, especially immunohistochemistry and DNA testing.
Description: Dr. Boccia describes cases in which he uses CancerTREATMENT NGS+ in his clinical practice.
Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.